Jason Hawthorne

Jason Hawthorne


Recent articles


1 Truth and 1 Misconception About How the Election Will Change Healthcare

The past 10 years can tell us a lot about what will happen in healthcare after the November election, and what won't.


Why Europe Is Looking to This Company for a Coronavirus Vaccine

CureVac is using the same messenger RNA approach that Moderna uses. Why is Moderna getting all the headlines?


1 Green Flag for Teladoc's Future

Investors were frightened by the $18.5 billion price tag for Livongo, but they might be missing the most important metric for valuing the company.


Is OPKO Health Stock a Buy?

Despite high-profile agreements to provide coronavirus testing, this small-cap company might not pass the test in the long term.


1 Red Flag for Teladoc's Future

Coronavirus relief packages eliminated restrictions on telemedicine. Growth for the company could hit a roadblock if these barriers are brought back.


Is It Too Late to Buy Livongo Stock?

The fast-growing chronic disease management company is getting swallowed up in one of the largest deals of the year, but it may not be too late to pick up shares.


Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?

Two small biotechs collaborated to find a coronavirus vaccine, but one of them may come out way ahead due to its expertise and other partnerships.


Does This Metric Tell Investors All They Need to Know About Gilead Sciences?

The company has stagnated since its revolutionary HIV and hepatitis C drugs were released, and one metric shows why investors should look elsewhere for returns.


Better Coronavirus Stock: AstraZeneca or Johnson & Johnson

These two pharma heavyweights are among the many players racing to get a COVID-19 vaccine approved.


Quidel and OPKO Health Are Scoring With Coronavirus Testing in Sports. Is the Market Missing It?

Successful partnerships with major sports leagues and updated guidance may mean coronavirus testing is here to stay.


Is Amwell Stock a Buy?

The stock has doubled since its hot IPO, but coronavirus-induced trends might not be enough to satisfy investors seeking outsized gains.


1 Reason to Sell Moderna Now

Brisk executive stock sales raise serious questions about why retail investors should buy shares of this coronavirus vaccine developer.


1 Reason to Buy Moderna Now

The company is developing a software for our bodies that could redefine medicine in the years ahead.


Where Will Teladoc Be in 5 Years?

The company should still be a compelling growth stock after the coronavirus, when things go back to normal (we hope). But investors might not care.


Better Buy: AbbVie vs. Johnson & Johnson

Both are large pharmaceutical companies, but these stocks have some huge differences that can help investors pick the better long-term investment.


2 Top Healthcare Stocks to Watch in October

These stocks could share big news this month, loosening the grip of the coronavirus on our lives.

HIV drugs in hands

Is Gilead Sciences a Buy?

Investors interested in Gilead Sciences need to look forward, not backward, to avoid the common trap of thinking history will repeat itself.


3 Stocks to Buy No Matter What Happens in November

Forget politics and a pandemic. The outlook for these stocks keeps getting better, and analysts can't keep up.

Taking Pill

Forget Snowflake! Buy This Ultra-High-Growth Stock

After doubling sales last year, this vaccine maker is speeding toward a revolution in the way humans prevent disease.


Next Coronavirus Market Correction: Where to Invest $5,000

When you have an opportunity to buy the best stocks on the cheap, don't outsmart yourself.